In less than a week’s time, Roche Holding’s stock took another significant hit, dropping 6.02% on Wednesday. This decline was driven by disappointing news regarding its experimental obesity medication, prompting investors to divest from the established pharmaceutical giant. By the close of trading, Roche’s market value had decreased by nearly 6%.
Contents
- 1 Obesity Drug Falls Short
- 2 A Risky Venture Worth Over $3 Billion
- 3 Don’t Miss This Second Chance at a Potentially Lucrative Opportunity
- 4 – Nvidia: A $1,000 investment when we doubled down in 2009 would now be worth $280,262!*
- 5 – Apple: A $1,000 investment when we doubled down in 2008 would now be worth $41,639!*
- 6 – Netflix: A $1,000 investment when we doubled down in 2004 would now be worth $363,277!*
Obesity Drug Falls Short
During the European Association for the Study of Diabetes meeting held that day, Roche shared findings from an early-stage clinical trial of its CT-996 pill. This initiative represents the Swiss-based company’s entry into the highly promising weight-loss drug sector, a market currently led by European counterpart Novo Nordisk’s Wegovy. Additionally, U.S. heavyweight Eli Lilly has recently joined the competition with its Zepbound product.
Regrettably for Roche, the latest study on CT-996 revealed adverse effects, including nausea, vomiting, and diarrhea. In the presentation on Wednesday, Roche noted that these side effects might be alleviated by gradually increasing the drug’s dosage. Patients who followed this approach experienced fewer adverse effects.
A Risky Venture Worth Over $3 Billion
Roche obtained CT-388, along with another investigational weight-loss treatment, through the acquisition of clinical-stage biotech firm Carmot Therapeutics. This transaction, potentially valued at up to $3.1 billion, was finalized in January. Despite a track record with notable achievements, Roche has recently encountered setbacks in trials for medications targeting Alzheimer’s disease and cancer. Success in the obesity drug sector could significantly bolster the company’s portfolio.
Don’t Miss This Second Chance at a Potentially Lucrative Opportunity
Do you ever feel like you’ve missed out on investing in top-performing stocks? If so, pay attention.
Occasionally, our team of expert analysts issues a “Double Down” stock recommendation for companies they believe are on the brink of a major upswing. If you’re concerned about having already missed your investment opportunity, now is the perfect time to act before it’s too late. The results speak for themselves:
– Nvidia: A $1,000 investment when we doubled down in 2009 would now be worth $280,262!*
– Apple: A $1,000 investment when we doubled down in 2008 would now be worth $41,639!*
– Netflix: A $1,000 investment when we doubled down in 2004 would now be worth $363,277!*
Currently, we’re issuing “Double Down” alerts for three remarkable companies, and such an opportunity may not arise again soon.
See 3 “Double Down” stocks ›
*Stock Advisor returns as of 09/11/2024
